Use of antidepressant serotoninergic medications and cardiac valvulopathy: a nested case-control study in the health improvement network (thin) database
British Journal of Clinical Pharmacology, 05/07/2012Lapi F et al.
These results would suggest that antidepressant serotoninergic medications (SMs) exposure is not associated with an increased risk of cardiac Valvulopathy (CV) .
Authors conducted a case–control study nested in a cohort of antidepressant SMs users selected from The Health Improvement Network database.
Patients who experienced a CV (index date) event during follow–up were cases.
Cases were ascertained in a random sample of them.
Up to 10 controls were matched to each case by sex, age, month and year of the study entry.
Antidepressant SMs use during follow–up was defined as current (the last antidepressant SMs prescription occurred in the 2 months before the index date), recent (in the 2–12 months before the index date) and past (≥ 12 months before the index date).
They fitted a conditional regression model to estimate the association between antidepressant SMs use and the risk of CV by means of Odds Ratios (OR) and corresponding 95% Confidence Intervals (CI).
Sensitivity analyses were conducted to test the robustness of the results.
The study cohort included 752,945 subjects aged 18–89 years.
Throughout follow–up 1663 (3.4 per 10,000 person–years) cases of CV were detected and were matched to 16566 controls.
The adjusted OR (95% CI) for current and recent users compared to past users of antidepressant SMs were 1.16 (0.96–1.40) and 1.06 (0.93–1.22), respectively.
Consistent effect estimates were obtained when considering cumulative exposure to antidepressant SMs during follow–up.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.